Portfoliotracker

Upstream Bio, Inc.

UPB · NASDAQGS · Healthcare Biotechnology 11/100 E

2,150 $
▼ −0,630 (−22,66 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 12:15
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score11 / 100 Market cap118 mil. $ P/E– Forward P/E-0,8 P/S41,0 P/B0,5 EV/EBITDA– Dividend yield– FCF yield– EPS-3,01 $ Net margin0,0 % Return on equity-53,5 % Beta1,61 Debt / equity0,00
52-week range 2,12 to 33,68
3-month average volume1,0 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.

Employees
75
Country
United States
Fiscal year end
31. 12.
Data since
11. 10. 2024

Explore further

Similar companies BCAXMBXZBIORAPPCTNM

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account